Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

JACC: Heart Failure

Volumn 5, Issue 4, 2017, Pages 287-296

  Aimo, Alberto ^a   Vergaro, Giuseppe ^a,b   Ripoli, Andrea ^b   Bayes Genis, Antoni ^c   Pascual Figal, Domingo A ^d   de Boer, Rudolf A ^e   Lassus, Johan ^f   Mebazaa, Alexandre ^g   Gayat, Etienne ^g   Breidthardt, Tobias ^h   Sabti, Zaid ^h   Mueller, Christian ^h   Brunner La Rocca, Hans Peter ⁱ   Tang, W H Wilson ^j   Grodin, Justin L ^k   Zhang, Yuhui ^l   Bettencourt, Paulo ^m   Maisel, Alan S ⁿ   Passino, Claudio ^a,b   Januzzi, James L ^o   Emdin, Michele ^a,b   more..

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b Fondazione Toscana G Monasterio   (Italy)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g AP HP Saint Louis and Lariboisière University Hospitals   (France)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j LERNER RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l PEKING UNION MEDICAL COLLEGE   (China)

^m University of Porto   (Portugal)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

more..

Author keywords

acute heart failure; meta analysis; prognosis; sST2

Indexed keywords

SOLUBLE SUPPRESSION OF TUMORIGENECITY 1; UNCLASSIFIED DRUG; IL1RL1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN;

ACUTE HEART FAILURE; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; EFFECT SIZE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN BLOOD LEVEL; ACUTE DISEASE; BLOOD; HEART FAILURE; META ANALYSIS; MORTALITY; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; CAUSE OF DEATH; HEART FAILURE; HOSPITALIZATION; HUMANS; INTERLEUKIN-1 RECEPTOR-LIKE 1 PROTEIN; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 85012879167     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.12.016     Document Type: Article

References (37)

1. 1 Kakkar, R., Lee, R.T., The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7 (2008), 827–840.
2. 2 Weinberg, E.O., Shimpo, M., Hurwitz, S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107 (2003), 721–726.
3. 3 Dieplinger, B., Mueller, T., Soluble ST2 in heart failure. Clin Chim Acta 443 (2015), 57–70.
4. 4 Januzzi, J.L., Mebazaa, A., Di Somma, S., ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. Am J Cardiol 115:Suppl (2015), 26B–31B.
5. 5 Januzzi, J.L., Pascual-Figal, D., Daniels, L.B., ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. Am J Cardiol 115:Suppl (2015), 70B–75B.
6. 6 Anand, I.S., Kempf, T., Rector, T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 122 (2010), 1387–1395.
7. 7 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
8. 8 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
9. 9 Aimo, A., Vergaro, G., Passino, C., et al. Prognostic value of soluble suppression of tumorigenicity-2 (sST2) in chronic heart failure: a meta-analysis. J Am Coll Cardiol HF 5 (2017), 280–286.
10. 10 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 6, 2009, e1000097.
11. 11 Viechtbauer, W., Conducting meta-analyses in R with the metafor package. J Stat Softw 36 (2010), 1–48.
12. 12 Felker, G.M., Fiuzat, M., Thompson, V., et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 6 (2013), 1172–1179.
13. 13 Higgins, J.P., Thompson, S.G., Deeks, J.J., Altman, D.G., Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
14. 14 Breidthardt, T., Balmelli, C., Twerenbold, R., et al. Heart failure therapy–induced early ST2 changes may offer long-term therapy guidance. J Card Fail 19 (2013), 821–828.
15. 15 Frioes, F., Lourenco, P., Laszczynska, O., et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol 104 (2015), 491–499.
16. 16 Gandhi, P.U., Gaggin, H.K., Belcher, A.M., et al. Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. Clin Chim Acta 445 (2015), 73–78.
17. 17 Lassus, J., Gayat, E., Mueller, C., et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 168 (2013), 2186–2194.
18. 18 Llibre, C., Zamora, E., Caballero, A., et al. The real-life value of ST2 monitoring during heart failure decompensation: impact on long-term readmission and mortality. Biomarkers 21 (2016), 225–232.
19. 19 Maisel, A., Xue, Y., van Veldhuisen, D.J., et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH study). Am J Cardiol 114 (2014), 737–742.
20. 20 Pascual-Figal, D.A., Manzano-Fernandez, S., Boronat, M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 13 (2011), 718–725.
21. 21 Sanders-van Wijk, S., van Empel, V., Davarzani, N., et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail 17 (2015), 1006–1014.
22. 22 Tang, W.H., Wu, Y., Grodin, J.L., et al. Prognostic value of baseline and changes in circulating soluble ST2 levels and the effects of nesiritide in acute decompensated heart failure. J Am Coll Cardiol HF 4 (2016), 68–77.
23. 23 Zhang, R., Zhang, Y., Zhang, J., et al. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure. PLoS One, 9, 2014, e110976.
24. 24 Deeks JJ, Higgins JPT, Altman DG, eds. Chapter 9: analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions. Available at: http://handbook.cochrane.org/chapter_9/9_analysing_data_and_undertaking_meta_analyses.htm. Accessed January 13, 2017.
25. 25 Demissei, B.G., Valente, M.A., Cleland, J.G., et al. Optimizing clinical use of biomarkers in high-risk acute heart failure patients. Eur J Heart Fail 18 (2016), 269–280.
26. 26 Bettencourt, P., Azevedo, A., Pimenta, J., et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004), 2168–2174.
27. 27 Sanada, S., Hakuno, D., Higgins, L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 (2007), 1538–1549.
28. 28 Dieplinger, B., Egger, M., Koehler, W., et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit—the Linz Intensive Care Unit (LICU) study. Clin Chim Acta 413 (2012), 587–593.
29. 29 Rudolf, J.W., Lewandrowski, E.L., Lewandrowski, K.B., et al. ST2 predicts mortality and length of stay in a critically ill noncardiac intensive care unit population. Am J Clin Pathol 145 (2016), 203–210.
30. 30 Brunner, M., Krenn, C., Roth, G., et al. Increased levels of soluble ST2 protein and IgG1 production in patients with sepsis and trauma. Intensive Care Med 30 (2004), 1468–1473.
31. 31 Boisot, S., Beede, J., Isakson, S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 14 (2008), 732–738.
32. 32 Henry-Okafor, Q., Collins, S.P., Jenkins, C.A., et al. Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomarkers J 2012 (2012), 1–8.
33. 33 Shah, K.B., Kop, W.J., Christenson, R.H., et al. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 57 (2011), 874–882.
34. 34 Dieplinger, B., Gegenhuber, A., Kaar, G., et al. Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 43 (2010), 714–719.
35. 35 Socrates, T., deFilippi, C., Reichlin, T., et al. Interleukin family member ST2 and mortality in acute dyspnoea. J Intern Med 268 (2010), 493–500.
36. 36 Januzzi, J.L. Jr., Peacock, W.F., Maisel, A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 50 (2007), 607–613.
37. 37 Aldous, S.J., Richards, A.M., Troughton, R., Than, M., ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. J Card Fail 18 (2012), 304–310.